ArticleMolecular biology reports2026
Cardamonin activates AMPK/FOXO3a/Nrf-2 axis to ameliorate oxidative stress in hyperlipidemia induced cardiac injury in mice.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHyperlipidemia (HLP) is a prevalent metabolic disorder that induces myocardial injury through prolonged oxidative stress. Cardamonin (CAR), a natural chalcone from the Zingiberaceae family, is recognised for its antioxidant and anti-inflammatory activities; however, its specific role and underlying mechanisms in cardiovascular protection against HLP remain to be fully elucidated. This study aimed to investigate the protective effects of CAR on HLP-induced cardiac damage. METHODS AND
resultsAn integrated approach combining network pharmacology and molecular docking was first employed to identify potential targets. Subsequently, in vivo experiments were conducted using C57BL/6J mice (n = 6 per group). HLP-induced cardiac injury models were established and treated with CAR. Network pharmacology and docking results revealed the AMP-activated protein kinase (AMPK)/forkhead box protein O3a (FOXO3a)/nuclear factor erythroid 2-related factor 2 (Nrf-2) signalling axis as a key target of CAR. The in vivo results demonstrated that CAR treatment significantly activated this pathway, thereby upregulating the expression of downstream antioxidant genes and alleviating oxidative stress. These molecular changes resulted in a significant reduction in myocardial histological damage and increased the expression of cardiac markers in HLP mice compared with those in the untreated group.
conclusionsCAR attenuates HLP-induced myocardial injury by activating the AMPK/FOXO3a/Nrf-2 axis to suppress oxidative stress. These findings provide new evidence for the therapeutic potential of CAR as a cardioprotective agent for managing hyperlipidemia-related complications.
Indexed as
Identifiers
42084787What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.